AU2022281104A1 - Bcma as a target for t cell redirecting antibodies in b cell lymphomas - Google Patents

Bcma as a target for t cell redirecting antibodies in b cell lymphomas Download PDF

Info

Publication number
AU2022281104A1
AU2022281104A1 AU2022281104A AU2022281104A AU2022281104A1 AU 2022281104 A1 AU2022281104 A1 AU 2022281104A1 AU 2022281104 A AU2022281104 A AU 2022281104A AU 2022281104 A AU2022281104 A AU 2022281104A AU 2022281104 A1 AU2022281104 A1 AU 2022281104A1
Authority
AU
Australia
Prior art keywords
bcma
cell
cells
specific antibody
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2022281104A
Other languages
English (en)
Inventor
Homer ADAMS III
Eric Frederik ELDERING
Arnon P. KATER
Raluca VERONA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amsterdam UMC Foundation
Janssen Biotech Inc
Original Assignee
Amsterdam UMC Foundation
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amsterdam UMC Foundation, Janssen Biotech Inc filed Critical Amsterdam UMC Foundation
Publication of AU2022281104A1 publication Critical patent/AU2022281104A1/en
Assigned to JANSSEN BIOTECH, INC., Stichting Amsterdam UMC reassignment JANSSEN BIOTECH, INC. Amend patent request/document other than specification (104) Assignors: ACADEMISCH MEDISCH CENTRUM, JANSSEN BIOTECH, INC.
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
AU2022281104A 2021-05-28 2022-05-26 Bcma as a target for t cell redirecting antibodies in b cell lymphomas Abandoned AU2022281104A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163194470P 2021-05-28 2021-05-28
US63/194,470 2021-05-28
US202163209694P 2021-06-11 2021-06-11
US63/209,694 2021-06-11
PCT/EP2022/064362 WO2022248642A1 (en) 2021-05-28 2022-05-26 Bcma as a target for t cell redirecting antibodies in b cell lymphomas

Publications (1)

Publication Number Publication Date
AU2022281104A1 true AU2022281104A1 (en) 2024-01-18

Family

ID=82115891

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022281104A Abandoned AU2022281104A1 (en) 2021-05-28 2022-05-26 Bcma as a target for t cell redirecting antibodies in b cell lymphomas

Country Status (10)

Country Link
US (1) US20220411525A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347039A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024519545A (cg-RX-API-DMAC7.html)
KR (1) KR20240014482A (cg-RX-API-DMAC7.html)
CN (1) CN119679935A (cg-RX-API-DMAC7.html)
AU (1) AU2022281104A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023024822A2 (cg-RX-API-DMAC7.html)
CA (1) CA3221399A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023014139A (cg-RX-API-DMAC7.html)
WO (1) WO2022248642A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116249548A (zh) 2020-05-11 2023-06-09 詹森生物科技公司 用于治疗多发性骨髓瘤的方法
EP4426437A4 (en) 2021-11-03 2025-09-17 Janssen Biotech Inc METHODS FOR TREATING CANCER AND ENHANCING THE EFFICACY OF BISPECIFIC BCMAXCD3 ANTIBODIES

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI811023B (zh) 2015-08-17 2023-08-01 美商健生生物科技公司 抗bcma抗體,結合bcma及cd3之雙特異性抗原結合分子及其用途
EP3615068A1 (en) * 2017-04-28 2020-03-04 Novartis AG Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
WO2019220368A1 (en) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
WO2021092060A1 (en) * 2019-11-05 2021-05-14 Engmab Sarl Methods of treatment

Also Published As

Publication number Publication date
BR112023024822A2 (pt) 2024-02-20
WO2022248642A1 (en) 2022-12-01
US20220411525A1 (en) 2022-12-29
CA3221399A1 (en) 2022-12-01
CN119679935A (zh) 2025-03-25
EP4347039A1 (en) 2024-04-10
KR20240014482A (ko) 2024-02-01
MX2023014139A (es) 2023-12-13
JP2024519545A (ja) 2024-05-15

Similar Documents

Publication Publication Date Title
US10604580B2 (en) Combination therapies with anti-CD38 antibodies
CN112513080B (zh) Vista抗原结合分子
TW202208429A (zh) 用於治療多發性骨髓瘤之方法
CN111565751A (zh) 治疗高危多发性骨髓瘤的方法
EP3221359A1 (en) Methods for tumor treatment using cd3xcd20 bispecific antibody
IL293834A (en) Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
EP4118105A2 (en) Cd80-fc fusion protein and uses thereof
RS59516B1 (sr) Kombinovane terapije sa anti-cd38 antitelima
JP2016534090A (ja) Cd38アゴニストの医学的使用
CA3232806A1 (en) B7-h4 antibody-drug conjugates for the treatment of cancer
CN112292399A (zh) 抗cd27抗体及其用途
EP4213945A1 (en) Methods for treating multiple myeloma
AU2023375177A1 (en) Methods of treating cancers
US20220411525A1 (en) Bcma as a target for t cell redirecting antibodies in b cell lymphomas
WO2021178814A1 (en) Anti-gitr antibodies and uses thereof
CN118043070A (zh) Bcma作为在b细胞淋巴瘤中t细胞重定向抗体的靶标
AU2022382978A1 (en) Methods of treating cancers and enhancing efficacy of gprc5dxcd3 bispecific antibodies
HK40110611A (en) Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EA050839B1 (ru) Способы лечения множественной миеломы
CA3124168A1 (en) Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: STICHTING AMSTERDAM UMC

Free format text: FORMER NAME(S): JANSSEN BIOTECH, INC.; ACADEMISCH MEDISCH CENTRUM

Owner name: JANSSEN BIOTECH, INC.

Free format text: FORMER NAME(S): JANSSEN BIOTECH, INC.; ACADEMISCH MEDISCH CENTRUM

MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period